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Summary 
Background: We assessed whether overnight home use of automated closed loop insulin delivery 
(artificial pancreas) improves glucose control.  
Methods: We studied 24 adults with type 1 diabetes in a multicentre crossover study design 
comparing four weeks of overnight closed loop using a model predictive control algorithm to direct 
insulin delivery, with four weeks of insulin pump therapy in which participants used real-time display of 
continuous glucose monitoring independent of their pumps as control. Primary outcome was time 
when glucose was in the target range of 3·9 and 8·0mmol/l between midnight to 07:00. Analyses were 
by intention to treat. Trial registration ClinicalTrials.gov NCT01440140. 
Findings: Closed loop was utilised over median 8·3 (interquartile range 6·0, 9·6)hours on 555nights 
(86%). Proportion of time when overnight glucose was in target range was significantly higher during 
closed loop compared to control by 13·5% (95% CI, 7·3-19·7; p<0·001). Mean overnight glucose 
(8·2±0·9 vs. 9·0±1·3mmol/l; p=0·005) and time spent above target (44·3%±11·9 vs. 57·1%±15·6; 
p=0·001) were significantly lower during closed loop. Time spent below target was low and 
comparable [1·8%( 0·6, 3·6) vs. 2·1%(0·7, 3·9);p=0·28]. Lower mean overnight glucose was brought 
about by increased overnight insulin delivery [6·4 (4·5, 8·1) vs. 4·9 (3·7, 6·3)units;p<0·001) without 
changing the total daily insulin amount [34·5 (29·3, 48·4) vs. 35·4 (29·7, 45·2)units;p=0·32]. No 
severe hypoglycaemia episodes occurred during control period and two during closed loop not related 
to algorithm instructions. 
Interpretation: Unsupervised overnight closed loop at home is feasible and may improve glucose 
control in adults with type 1 diabetes. 
 
3 
Introduction 
 Intensive insulin therapy has been the standard of care in the management of type 1 diabetes 
since the Diabetes Control and Complications Trial
1
. However, tightening glycaemic control increases 
the risk of hypoglycaemia
2,3
, alleviated in part by modern insulin analogues
4
 and educational 
interventions in adults
5
 but not youth
6
. Individuals with type 1 diabetes continue to face daily 
challenges of complex insulin regimes involving multiple daily insulin boluses, frequent blood glucose 
monitoring, and unpredictable glucose excursions
7
. Recent advances in diabetes technology 
have highlighted their increasing role in clinical care. Continuous glucose monitoring devices measure 
interstitial glucose every one to five minutes leading to improved glycaemic control
8
. Randomised 
control trials demonstrated the benefits of sensor-augmented pump therapy in reducing HbA1c
9
. The 
advent of the threshold suspend feature allows insulin delivery to be suspended automatically for up 
to two hours and has been shown to reduce the duration and frequency of hypoglycaemia
10,11
.  
 Closed loop insulin delivery, known as the artificial pancreas, is a novel approach which is 
more complex and differs from conventional pump therapy and the threshold suspend approach 
through a control algorithm that autonomously increases and decreases subcutaneous insulin delivery 
based on real-time sensor glucose levels thereby mimicking physiological insulin delivery
12
. Clinical 
research facility studies have demonstrated closed loop insulin delivery to be a feasible and safe 
improving glycaemic control and reducing the risk of hypoglycaemia
13-15
.   
Follow-up transitional and ‘out-of-hospital’ single night studies have been promising
16,17
 
paving the way towards developing ambulatory closed loop prototypes such as that used in a three-
week single centre study in adolescents
18
. In the present study, we hypothesised that four-week 
overnight unsupervised closed loop insulin delivery at home in adults may improve glycaemic control 
without increasing the risk of hypoglycaemia.  
 
4 
Methods 
 
Participants and study design  
We identified eligible adults from diabetes clinics attending Addenbrooke’s Hospital, 
Cambridge, Sheffield Teaching Hospitals, Sheffield, and King’s College Hospital, London. Inclusion 
criteria were type 1 diabetes (World Health Organisation criteria), C-peptide negative, age 18 years 
and older, insulin pump therapy for at least 3 months, knowledge of insulin self-adjustment, 
performing glucose self-monitoring at least four times daily, and HbA1c≤10% (86mmol/mol). Exclusion 
criteria included established nephropathy, neuropathy or proliferative retinopathy, total daily insulin 
dose ≥2·0U/kg, regular use of continuous glucose monitoring within one month prior to enrolment, 
severe visual or hearing impairment, pregnancy or breast feeding. All participants signed informed 
consent prior to the start of study-related procedures. The study protocol was approved by the East of 
England Central Cambridge Ethics Committee.  
  
Figure 1 outlines the open label randomised controlled cross-over study design. Following the run-in 
phase, participants applied insulin pump therapy with real-time continuous glucose monitoring at 
home on two periods with or without overnight closed loop. Each period lasted four weeks,   Identical 
study insulin pump and real-time continuous glucose monitoring device were used during the two 
study periods, which were separated by a three to four-week washout during which participants used 
their own pump and discontinued continuous glucose monitoring. 
 
Randomisation and masking 
 The order of the two study periods was random and was determined following the run-in 
phase using computer generated permuted block randomisation. During the run-in phase, the 
continuous glucose monitor receiver was modified and participants were blinded to the recorded 
sensor glucose levels. Participants had access to sensor glucose readings after the end of the run-in 
phase.  
 
Procedures 
 On enrolment, participants were trained on the study insulin pump (Dana R Diabecare, Sooil, 
Seoul, South Korea) and continuous glucose monitoring device (FreeStyle Navigator, Abbott Diabetes 
Care, Alameda, CA, USA). Participants calibrated the real-time continuous glucose monitoring device 
according to manufacturer’s instructions. During the run-in phase, we assessed compliance by 
assessing the number of days continuous glucose monitoring data were available from sensor 
glucose downloads.  Each participant was required to use the study pump and continuous glucose 
monitor for at least two weeks. Downloaded sensor  glucose readings at the end of the run-in phase 
were used to optimise insulin pump therapy. Participants used rapid acting insulin analogue normally 
used in their usual clinical care. The built-in bolus wizard of the study insulin pump was used by 
participants during both interventions to calculate insulin boluses at mealtimes and also when 
administering correction boluses.   
5 
 During the control period, participants used real-time continuous glucose monitor and the 
study pump. The sensor glucose alarm threshold for hypoglycaemia was initially set at 3·5mmol/l but 
could be modified by the participants. During the closed loop period, participants were admitted to the 
local clinical research facility for their first closed loop night and received training on the closed loop 
system which was used under supervision overnight. Training lasted 60 to 90minutes and covered 
initiation and discontinuation of the closed loop system as well as problem troubleshooting. 
Participants were trained to perform calibration checks before evening meal; if sensor glucose was 
above capillary glucose by more than 3mmol/l, the continuous glucose monitor was re-calibrated and 
calibration check was repeated before starting closed loop. These instructions reduced the risk of 
sensor error and the calibration check approach was effective when assessed by computer 
modelling
19
. If sensor glucose readings became unavailable or in case of other system failures, 
participants were alerted by an audible alarm and the system restarted participant’s usual insulin 
delivery rate within 30 to 60 minutes to mitigate the risk of insulin under- and over-delivery
20
.  
 From the following night, participants used the closed loop system unsupervised at home for 
four weeks. Participants were instructed to initiate the system at home following their evening meal, 
and to discontinue it before breakfast the next morning. Participants were not restricted in dietary 
intake or daily activities. A 24-hour telephone support assisted participants in clinical or technical 
issues that arose during the study. Standard local hypoglycaemia and hyperglycaemia treatment 
guidelines were followed.  
Blood samples for HbA1c, fructosamine, random glucose and C-peptide measurements were 
taken after enrolment. HbA1c and fructosamine were additionally measured before and after each 
study period.  
 
Closed loop control algorithm 
 The Florence automated closed loop system
21
 comprised a model predictive control (MPC) 
algorithm residing on a handheld computer linked by cable to the continuous glucose monitoring 
receiver. Every 12 minutes, the treat-to-target algorithm calculated a new insulin infusion rate, which 
was automatically set on the study pump using wireless communication. The calculations utilised a 
compartment model of glucose kinetics
22
 describing the effect of rapid-acting insulin and the 
carbohydrate content of meals on glucose levels. The algorithm was initialised using pre-programmed 
basal insulin delivery. Participant’s weight and total daily insulin dose were entered at setup by the 
research team on the first night of closed loop. Carbohydrate intake data entered by participants into 
the insulin pump built-in bolus wizard was automatically downloaded to the handheld computer when 
closed loop was turned on.  Insulin delivery history, including manually instructed insulin boluses, was 
also automatically downloaded. The algorithm included rules that limited maximum insulin infusion 
and suspended insulin delivery if glucose was at or below 4·3mmol/l or when glucose was rapidly 
decreasing. Algorithm version 0·3·24 was used (University of Cambridge). 
 
 Assays 
6 
 We used a chemiluminescence immunoassay (Diasorin Liaison XL, Deutschland GmbH, 
Dietzenbach, Germany; inter-assay CV 5·6% at 563pmol/l, 4·5% at 2529pmol/l, 5·8% at 5449pmol/l) 
to measure baseline plasma C-peptide. We determined fructosamine using an enzymatic assay 
(Randox, Antrim, United Kingdom; interassay CVs 9·5% at 193 µmol/l, 6·4% at 430µmol/l, 5·2% at 
669µmol/l). HbA1c was measured centrally using ion exchange high performance liquid 
chromatography (G8 HPLC Analyzer, Tosoh Bioscience Inc., CA, US; interassay CVs 1·3% at 31·2 
mmol/mol, 0·8% at 80·5mmol/mol). 
 
Sample size 
 The power calculation was based on a previous study
14
. We anticipated that overnight closed 
loop insulin delivery would increase the percentage night-time glucose was between 3·9 and 
8·0mmol/l by a mean 13% (SD 25%). We calculated that 24 participants would provide 80% power at 
the 5% level of significance to detect such difference between sensor-augmented pump therapy and 
overnight closed loop insulin delivery.  
 
Statistical analysis 
 The statistical analysis plan was agreed upon by investigators in advance. The analyses were 
performed on an intention to treat basis. Each night was analysed to the treatment group assigned. 
The primary efficacy outcome was the time spent in the target glucose range (3·9 to 8·0mmol/l) 
between midnight and 07:00 as recorded by CGM. Secondary outcomes included mean glucose, time 
spent below 3·9mmol/l (hypoglycaemia) and above 8·0mmol/l (hyperglycaemia), and insulin delivery. 
Glucose variability overnight was assessed by the standard deviation and the coefficient of variation 
of CGM levels. Hypoglycaemia burden was assessed by calculating the glucose sensor area under 
the curve less than 3·5mmol/l and the number of nights with sensor glucose less than 3·5mmol/l for at 
least 20minutes. Outcomes were additionally calculated using adjusted sensor glucose assuming a 
15% measurement error to correct for bias resulting from simultaneous use of sensor glucose to 
direct insulin delivery
23
. Secondary outcomes were calculated from midnight to 07:00 and over the 24 
hour period. Differences in HbA1c and plasma fructosamine levels were calculated to determine 
changes in metabolic control. 
 Outcomes were calculated using GStat software, Version 2·0 (University of Cambridge, 
Cambridge, UK) and statistical analyses using SPSS, Version 21 (IBM Software, Hampshire, UK). 
Normally distributed data were compared using paired t-test while non-normally distributed data using 
Wilcoxon signed rank test. To assess end-period HbA1c, a regression model adjusted for pre-period 
HbA1c level was fitted to compare the two treatments. A similar analysis was carried out to assess 
changes in fructosamine. Values are reported as mean±SD or median (quartile 1, quartile 3), unless 
stated otherwise. All p-values are two-tailed and values less than 0·05 were considered statistically 
significant.  
 
Role of the funding and support sources 
7 
No sponsor had any role in the study design, data collection, data analysis, data interpretation, or 
writing of the report. Abbott Diabetes Care read the manuscript before submission. The corresponding 
author had full access to all the data in the study and had final responsibility for the decision to submit 
the publication.  
 
Results 
 Twenty-seven participants were recruited from December 2012 to September 2013.  Figure 2 
shows flow of participants through the study. Two participants withdrew during the run-in phase. 
Twenty-five eligible participants were randomised; nine from Addenbrooke’s Hospital Cambridge, 
eight from King’s College Hospital London, and eight from Sheffield. One participant withdrew consent 
following randomisation. Data from 24 participants completing the study were analysed. Table 1 
summarises baseline characteristics.  
Primary and secondary analyses are shown in Table 2. The time when overnight sensor 
glucose was in target range, was significantly increased by a mean 13·5% (95% CI, 7·3-19·7, 
p<0·001) during overnight closed loop insulin delivery. No period (p=0·77) or carry-over effect 
(p=0·84) on primary endpoint was detected.  Sensor glucose profiles are shown in Figure 3. In all but 
three participants, closed loop improved time spent in target range (Figure 4).  In one of the three 
participants, time spent in hypoglycaemia was reduced by 15·1% and in the other two by 2·4% and 
2·7%. Closed loop reduced mean overnight glucose and time above target range without increasing 
time spent in the hypoglycaemia range. Time spent in hypoglycaemia below 3·9mmol/l was low 
(median time less than 10 minutes per night) and comparable during the two study periods. There 
were no significant differences in the burden of hypoglycaemia as measured by the AUC below 3·5 
mmol/l (p=0·61), number of nights during the study when sensor glucose was less than 3·5mmol/l for 
at least 20minutes (p=0·18) and the low blood glucose index
24
 (p=0·44). 
 Increased time spent in target range and reduced mean overnight glucose (Table 2 and 
Figure 4) was brought about by closed loop delivering 30% more insulin overnight (Table 3 and Figure 
3, bottom panel) but total daily insulin delivery did not differ between the two study interventions 
(Table 3). Overnight closed loop was utilised on 555 nights (86%); turned on at 22:52 (22:05, 23:44) 
and turned off at 07:23 (06:41, 08:29) operating over 8·3 (6·0, 9·6) hours (Table 4). Closed loop was 
unintentionally interrupted on average every 41 hours (once every 5 nights). The commonest cause 
(over 60%) of interruptions was the loss of wireless connectivity between handheld computer and 
insulin pump (Table 4). Other causes included inability to initiate closed loop cycle within 30 minutes, 
glucose sensor unavailability, and change of temporary infusion by user. Participants contacted the 
24hour support line approximately four times during the closed loop period.  
Overnight glucose variability measured as the standard deviation was comparable during the 
two interventions. The coefficient of variation of overnight glucose within each night was increased 
during closed loop. Conversely, a trend towards a reduced between-nights coefficient of variation was 
observed during closed loop, accompanied by consistently lower morning glucose (Table 2). This was 
not associated with increased time spent below 3·9mmol/l or AUC below 3·5mmol/l (Supplementary 
material, Table S1). Outcomes based on adjusted sensor glucose values were in concordance with 
8 
outcomes based on unadjusted sensor glucose; the proportion of time when adjusted overnight 
glucose was in target increased during closed loop compared to sensor-augmented therapy by a 
mean of 13·4% (p<0·001). Time above target was reduced by a mean of 11·9% (p=0·001) and time 
below target was comparable [2·2 (0·7, 3·9) vs. 2·5 (1·0, 4·5) %, p=0·21]. 
 Endpoints calculated from midnight to midnight are shown in Table 5. Overnight closed loop 
significantly reduced 24-hour glucose by 0·5mmol/l (p<0·001) and increased proportion of time spent 
within wider target range (p=0·002). Similar to the overnight period analyses, time when glucose was 
above 10·0mmol/l was significantly reduced. Participants performed on average eight capillary 
glucose measurements per day. Overall sensor accuracy in relation to capillary glucose was good 
with the median absolute deviation 0·8 (0·3, 1·5)mmol/l and the median absolute relative deviation of 
10·4% (4·7, 19·3). Seventy-eight percent of values were in Clarke Error Grid zone A. Median absolute 
relative deviation of sensor glucose during closed loop and control interventions was 10·1% and 
10·7%, respectively. 
Closed loop reduced HbA1c whilst no change was observed during control (7·9%±0·8 vs. 
7·7%±0·8, pre- vs. post-closed loop; 7·9%±0·7 vs. 7·9%±0·8, pre- vs. post-control; p=0·033). 
Fructosamine was unchanged (460±76 vs. 454±77; 458±98 vs. 464±84μmol; p=0·754). 
Two participants with history of hypoglycaemia unawareness each had an episode of severe 
hypoglycaemia during the closed loop period (Supplementary material, Figure S1 and S2).  Both 
events occurred at a time when closed loop was not operational and one subject was receiving 
standard while the other 50% of standard insulin pump therapy insulin rate. A post-hoc analysis 
identified that closed loop was interrupted about an hour prior to these events due to lack of wireless 
connectivity with insulin pump and at the time when insulin delivery was suspended due to predicted 
low glucose levels. The events were not attributable to control algorithm insulin advice and, whilst it is 
not possible to know the cause of the episodes definitely, they were likely compounded by increased 
physical activity during the day in one participant, and a user-error resulting in over-delivery of insulin 
whilst changing pump infusion set at night in the second participant. Both participants recovered fully 
without any clinical sequelae. 
No other episodes of severe adverse events and no episodes of hyperglycaemia with ketosis 
were reported. Four participants had mild to moderate respiratory tract infections during the closed 
loop period and one during control period. Two participants had viral gastroenteritis episodes during 
the closed loop period.  One participant underwent an elective inguinal hernia repair during the 
washout period and continued the study after recovery.  
     
9 
Discussion 
 
 We demonstrated the feasibility of four-week home use of overnight closed loop insulin 
delivery in adults. Glucose control improved including increased time spent in the target range and 
reduced mean glucose by delivering 30% more insulin overnight. During closed loop intervention, 
glucose levels remained lower compared to control throughout the day-time after closed loop was 
stopped (Supplementary material, Table S2), allowing participants to give less insulin bolus during 
breakfast and dinner periods (Supplementary material, Table S3). As a result, total daily insulin 
amount during both interventions were comparable. Time spent in hypoglycaemia was low with few 
nights with glucose below 3·5mmol/l during both interventions.  
 Achieving glycaemic level within the euglycaemic range, as safely as possible, presents a 
major challenge in type 1 diabetes. The risk of hypoglycaemia is increased when glycaemic control is 
tightened
25
. Threshold suspend pump therapy, which allows insulin delivery to be automatically 
suspended for up to two hours when sensor glucose falls below a preset threshold, represents the 
first step towards glucose responsive insulin delivery. Studies in children and adults report reductions 
in the frequency and duration of nocturnal hypoglycaemia in those at greatest risk
26,27
. However, the 
threshold suspend approach is not designed to step up insulin delivery and does not address the 
problem of overnight hyperglycaemia. Following the use of masked continuous glucose monitoring 
during the run-in period, participants utilised real-time sensor glucose during the control intervention 
to reduce time spent in hypoglycaemia demonstrating that the primary driver for these subjects was 
hypoglycaemia avoidance (Supplementary material, Tables S4 and S5). During control intervention, 
glucose outcomes were similar between Week 1 and Week 4 indicating rapid settling of glucose 
levels once real-time continuous glucose monitoring was initiated (Supplementary material, Table S6). 
Corrected for baseline HbA1c, continuous glucose monitoring data collected during control 
intervention were comparable to the JDRF continuous glucose monitoring trial
8
; the latter recruited 
adults with baseline HbA1c of 7·6% achieving mean glucose levels of 68% in the target range 
between 3·9 and 10·0mmol/l over 24 hours and 4·2% below 3·9mmol/l. The present study recruited 
adults with a slightly higher baseline HbA1c of 8·1% reflected by a lower time in the target range of 
60% and a lower time spent in hypoglycaemia of 1·7%. 
The advantage of a closed loop system such as ours is the finely tuned modulation of insulin 
delivery below and above the preset pump regimen. Day-to-day variations in insulin sensitivity are 
present in individuals with type 1 diabetes
28
. Using information from participant’s total daily insulin 
dose, basal insulin requirements and sensor glucose values, our control algorithm was able to adapt 
and safely cope with variations in overnight insulin requirements trading variability in insulin delivery 
for glucose consistency (Figure 3).    
Early overnight closed loop studies with our model predictive control algorithm in the research 
facility setting showed increased time spent in the target range and reduced time spent in 
hypoglycaemia
14,29
. A single centre three-week overnight closed loop study in the home setting 
demonstrated improved glucose control and fewer nights with sensor glucose below 3·5mmol/l (10% 
vs. 17%) in adolescents
18
. Prior to the present study, no other study had been conducted assessing 
the safety and efficacy of unsupervised closed loop at home in adults for a period longer than one 
10 
week. A four week study intervention period was considered sufficient to provide useful experience 
with unsupervised overnight closed loop home use by adults, and to allow progression to longer 
studies.  Although nights with glucose level below 3·5mmol/l were not significantly different, we 
observed lower baseline hypoglycaemia compared to previous studies
16
 with median time of less than 
10 minutes spent below 3·9mmol/l per night. Demonstrating reductions in hypoglycaemia will be 
difficult to achieve without studying a larger or more hypoglycaemia prone population. 
 The strength of our study is its multicentre design, allowing the assessment of a novel 
technology over a wider patient demographic demonstrating generalizability. No restrictions were 
placed on participants’ dietary intake or physical activity assessing system’s performance during free 
living conditions. Previous trials demonstrated improved glucose control with continuous glucose 
monitoring alone particularly in regular users
8
. Our study was limited by a duration of the control 
period which was too short to demonstrate a fall in HbA1c observed in previous trials of  continuous 
glucose monitoring over three months or longer.  Nevertheless, compliance with continuous glucose 
monitoring was high with most participants using it regularly during this period. Regular use of 
hyperglycaemia threshold alarms and further increase in nocturnal insulin supplementation during the 
control period might have diminished the difference in mean glucose between the two interventions. 
However, this might have resulted in more hypoglycaemia during the control intervention, or reduced 
sensor glucose use compliance due to alarm fatigue. Longer duration studies may provide additional 
information. We adopted cross-over design which had the benefit of each subject serving as its own 
control and the possible confounding period or carry-over effects were not detected. The study was 
limited by disruptions of wireless connectivity and other reasons causing closed loop to be interrupted 
on average every five nights. Improved connectivity and reliability of follow up prototypes may further 
increase usage above the present in excess of 85%.  
 In conclusion, unsupervised overnight closed loop at home is feasible and may improve 
glucose control in adults with type 1 diabetes. Longer term assessments are needed to strengthen the 
evidence of overnight closed loop benefits using systems with improved reliability.   
 
Panel. Research in context 
Systematic review 
We searched PubMed for articles published up to 24 January 2014 with the search terms (“closed 
loop” OR “artificial pancreas”) AND “type 1 diabetes”, and identified four randomised controlled trials 
which assessed closed loop use outside hospital settings. No multicentre randomised control trial in 
adults at home has been performed to date with or without remote monitoring, or of similar duration to 
the present study. A single night study at a diabetes youth camp involving remote monitoring showed 
reduction in the number of hypoglycaemic episodes with high baseline levels of hypoglycaemia; 
however no significant improvement in the median glucose values overnight was observed
16
. A 48-
hour home study using a portable bi-hormonal closed loop system, combining the delivery of insulin 
with subcutaneous glucagon did not show any improvement in time spent within target range. 
Reduction of median glucose on the second day of closed loop period was shown, but at the expense 
of greater time spent in the hypoglycaemic range
30
. An interim analysis of overnight closed loop over 
11 
four nights at home demonstrated improvements in hypoglycaemia endpoints, without improvement in 
the percentage of nights with normal mean glucose levels
31
. The only unsupervised single centre 
study published was one of three week duration in adolescence
18
. The reported benefits of overnight 
closed loop included increased time when glucose is in target, reduced mean glucose, and fewer 
nights with hypoglycaemia. 
Interpretation 
The use of overnight closed loop at home for an extended period without remote monitoring or 
continuous supervision is feasible in adults with type 1 diabetes. We showed improved time spent in 
target range and reduced glucose. These improvements were achieved by increasing insulin delivery 
overnight but without changing the total daily insulin delivery or the time spent in hypoglycaemia.  
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Table 1. Baseline characteristics (n = 24). 
Gender (M/F) 13/11* 
Age (years) 43±12 
BMI (kg/m
2
) 26·0±3·5 
HbA1c (%) 8·1±0·8 
HbA1c (mmol/mol) 65±9 
Duration of  diabetes (years) 29±11 
Duration on pump (years) 6·3±4·4 
Total daily insulin (U/kg/day) 0·5±0·1 
 
                                  * All C-peptide < 33pmol/l 
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Table 2. Comparison of overnight glucose control from midnight to 07:00 during closed loop and 
control period using unadjusted (raw) sensor glucose over 28 days in the home setting. 
 
Closed loop 
(n=24) 
Control  
(n=24) 
Paired 
difference* 
(n=24) 
p value
 
Mean glucose (mmol/l)
 
8·2±0·9 9·0±1·3 -0·8±1·3 0·005 
SD of glucose (mmol/l)
 
2·0±0·3 1·9±0·3 0·1±0·4 0·18 
Within night CV of glucose (%)
 
24±3 21±4 3±6 0·01 
Between nights CV of glucose (%)
 
26±6 29±7 -3±9 0·11 
Time spent at glucose level (%)     
3·9 to 8·0mmol/l
†, 
 52·6±10·6 39·1±12·8 13·5±14·7 <0·001 
3·9 to 10·0mmol/l
 
73·2±9·0 61·2±13·7 12·0±14·2 <0·001 
> 8·0mmol/l
 
44·3±11·9 57·1±15·6 -12·8±16·5 0·001 
> 16·7mmol/l**
 
1·1 (0·0, 2·8) 1·5 (0·1, 3·4) -0·0(-1·6, 0·5) 0·54 
< 3·9mmol/l**
 
1·8 (0·6, 3·6) 2·1 (0·7, 3·9) -0·3 (-2·4, 1·0) 0·28 
< 3·5 mmol/l**
 
0·7 (0·3, 1·4) 0·7 (0·3, 2·0) 0·3 (-17·4, 3·4) 0·3 
< 2·8mmol/l**
 
0·2 (0·0, 0·7) 0·2 (0·0, 1·3) 0·0 (-0·9, 0·2) 0·63 
AUCDay below 3·5mmol/l**       
(mmol/l × minutes) 
4·0 (0·8, 15·1) 5·3 (0·4, 25·6) 0·3 (-17·4, 3·8) 0·61 
     Number of nights when glucose 
<3·5mmol/l
‡
 
36 (5·4%) 58 (8·6%) - 0·18 
LBGI**
 
0·67 (0·27, 0·96) 
0·62 (0·25, 
1·21) 
-0·02 (-0·69, 
0·32) 
0·44 
Glucose at 21:00 (mmol/l)
 
8·6±0·9 9·3±1·3 -0·6±1·3 0·02 
Glucose at midnight (mmol/l)
 
9·2±1·3 9·2±1·7 0·01±1·2 0·9 
Glucose at 07:00 (mmol/l)
 
7·2±0·9 8·8±1·2 -1·6±1·5 <0·001 
 
*
 
Closed loop minus control. Positive value indicates measurement was higher on night of closed loop 
delivery compared with night of control 
Data are presented as mean ± SD, or
 
**median (interquartile range)  
†
 Primary endpoint 
‡
 Number of nights over four weeks when sensor glucose was < 3·5mmol/l for at least 20 minutes. 
LBGI = low blood glucose index; CGM = continuous glucose monitoring 
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Table 3. Insulin delivery overnight (00:00 – 07:00) and over 24-hour period. 
 
 
Closed loop 
(n=24) 
Control 
(n=24) 
p value 
Overnight insulin delivery (U)*  6·4 (4·5, 8·1) 4·9 (3·7, 6·3) <0·001 
Total daily insulin delivery (U)*
 
34·5 (29·3, 48·4) 35·4 (29·7, 45·2) 0·32 
SD of overnight insulin delivery (U) 0·6±0·2 0·1±0·1 <0·001 
 
Data shown are mean ± SD, or *median (interquartile range)  
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Table 4. Utility and failure analysis of closed loop operation.  
Number of nights when closed loop turned on 555 (86%) 
Time of day when closed loop turned on*
 
22:52 (22:05, 23:44)
 
Time of day when closed loop turned off* 07:23 (06:41, 08:29)
 
Duration of closed loop operation (hours)* 8·3 (6·0, 9·6)
 
Total duration of closed loop operation (h)  4613 
Number of events when closed loop interrupted (% of 
total interruptions) 
 
        lack of pump connectivity 68 (61) 
        unable to start closed loop cycle within 30 mins                                   21 (20) 
        sensor data unavailability 7 (6) 
        Temporary infusion changed by user 7 (6) 
        extended bolus changed by user 4 (4) 
        handheld computer operating system failure 4 (4) 
        handheld computer software system error 1 (1) 
  
* Median (interquartile range) from all study nights when closed loop turned on  
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Table 5. Comparison of 24-hour glucose control during closed loop and control using unadjusted 
(raw) sensor glucose over 28 days in the home setting. 
 
Closed loop 
(n=24) 
Control 
 (n=24) 
Paired 
difference* 
(n=24) 
p value
 
Mean glucose (mmol/l) 8·7±0·8 9·3±1·1 -0·5±0·7 0·001 
SD of glucose (mmol/l) 2·9±0·4 2·9±0·4 -0·0±0·3 0·79 
Within day CV of glucose (%)** 
34·1 (31·1, 
35·8) 
32·6 (30·0, 
34·1) 
1·9 (-0·6, 3·4) 0·02 
Between day CV of glucose (%)**
 14·9 (12·4, 
16·6) 
15·3 (13·6, 
21·3) 
-- 0·11 
Time spent at glucose level (%)     
3·9 to 10·0mmol/l 66·0±7·7 59·7±10·8 6·4±8·7 0·002 
>10·0mmol/l 30·8±9·3 37·3±12·3 -6·5±8·7 0·001 
> 16·7mmol/l**
 
1·9 (1·0, 2·9) 2·2 (1·0, 3·0) -0·6 (-1·2, 0·5) 0·33 
< 3·9mmol/l**
 
1·7 (0·9, 3·1) 1·7 (1·1, 3·5) -0·2 (-1·8, 0·5) 0·27 
< 3·5mmol/l**
 
0·8 (0·4, 1·4) 0·7 (0·5, 1·6) -0·2 (-0·8, 0·3) 0·11 
< 2·8mmol/l**
 
0·2 (0·0, 0·6) 0·2 (0·1, 0·6) 0·0 (-0·3, 0·2) 0·84 
AUCDay below 3·5mmol/l       
(mmol/l × minutes)**
 4·7 (1·3, 11·9) 4·5 (1·8, 17·2) -0·2 (-7·2, 1·9) 0·42 
LBGI**
 0·57 (0·36, 
0·84) 
0·54 (0·34, 
0·96) 
0·0 (-0·5, 0·2) 0·57 
 
*
Closed loop minus control. Positive value indicates measurement was higher during closed loop 
delivery intervention compared with control 
Data shown are mean ± SD, or **median (IQR) 
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. 
Figure 1. Study design comparing overnight closed loop insulin delivery with control. The outline 
shows when continuous glucose monitoring data were collected, efficacy assessed, and adverse 
events monitored.  
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Figure 2. Flow of participants through the trial. 
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Figure 3. Median (interquartile range) of sensor glucose (top panel) and insulin delivery (bottom 
panel) during closed loop (solid red line and red shaded area) and control (dashed black line and gray 
shaded area) period for the 24-hour duration. The glucose range 3·9 to 8·0 mmol/l is denoted in the 
top panel by horizontal dashed lines. 
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Figure 4. Individual values of time when glucose was in target glucose range from 3·9 to 8·0 mmol/l 
(left panel) and mean overnight glucose (right panel) (n=24).  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
References 
1. The effect of intensive treatment of diabetes on the development and progression of long-term 
complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research 
Group. N Engl J Med 1993; 329(14): 977-86. 
2. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT 
Research Group. Am J Med 1991; 90(4): 450-9. 
3. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Self-report of 
hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract 2013; 
19(5): 792-9. 
4. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 
1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11(4): 372-8. 
5. Rankin D, Cooke DD, Clark M, et al. How and why do patients with Type 1 diabetes sustain their use 
of flexible intensive insulin therapy? A qualitative longitudinal investigation of patients' self-management 
practices following attendance at a Dose Adjustment for Normal Eating (DAFNE) course. Diabet Med 2011; 
28(5): 532-8. 
6. Murphy HR, Wadham C, Hassler-Hurst J, Rayman G, Skinner TC, Group FaACaTSF. Randomized 
trial of a diabetes self-management education and family teamwork intervention in adolescents with Type 1 
diabetes. Diabet Med 2012; 29(8): e249-54. 
7. Aschner P, Horton E, Leiter LA, Munro N, Skyler JS, Management GPfED. Practical steps to 
improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective 
Diabetes Management. Int J Clin Pract 2010; 64(3): 305-15. 
8. Group JDRFCGMS. Effectiveness of continuous glucose monitoring in a clinical care environment: 
evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. 
Diabetes Care 2010; 33(1): 17-22. 
9. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 
diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012; 55(12): 3155-62. 
10. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction 
of hypoglycemia. N Engl J Med 2013; 369(3): 224-32. 
11. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin 
pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients 
with type 1 diabetes: a randomized clinical trial. JAMA 2013; 310(12): 1240-7. 
12. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011; 
7(7): 385-95. 
13. Sherr JL, Cengiz E, Palerm CC, et al. Reduced hypoglycemia and increased time in target using closed-
loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes. Diabetes 
Care 2013; 36(10): 2909-14. 
14. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial 
pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342: d1855. 
15. Luijf YM, DeVries JH, Zwinderman K, et al. Day and night closed-loop control in adults with type 1 
diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus 
patient self-management. Diabetes Care 2013; 36(12): 3882-7. 
24 
16. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes 
camp. N Engl J Med 2013; 368(9): 824-33. 
17. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: 
first studies of wearable artificial pancreas. Diabetes Care 2013; 36(7): 1851-8. 
18. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 
1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2014; 37(5): 1204-11. 
19. Wilinska ME, Chassin LJ, Acerini CL, Allen JM, Dunger DB, Hovorka R. Simulation environment to 
evaluate closed-loop insulin delivery systems in type 1 diabetes. J Diabetes Sci Technol 2010; 4(1): 132-44. 
20. Wilinska ME, Budiman ES, Taub MB, et al. Overnight closed-loop insulin delivery with model 
predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci 
Technol 2009; 3(5): 1109-20. 
21. Elleri D, Allen JM, Biagioni M, et al. Evaluation of a portable ambulatory prototype for automated 
overnight closed-loop insulin delivery in young people with type 1 diabetes. Pediatr Diabetes 2012; 13(6): 449-
53. 
22. Hovorka R, Shojaee-Moradie F, Carroll PV, et al. Partitioning glucose distribution/transport, disposal, 
and endogenous production during IVGTT. Am J Physiol Endocrinol Metab 2002; 282(5): E992-1007. 
23. Hovorka R, Nodale M, Haidar A, Wilinska ME. Assessing performance of closed-loop insulin delivery 
systems by continuous glucose monitoring: drawbacks and way forward. Diabetes Technol Ther 2013; 15(1): 4-
12. 
24. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment 
of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes 
Care 1998; 21(11): 1870-5. 
25. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57(12): 3169-76. 
26. Ly TT, Nicholas JA, Retterath A, Davis EA, Jones TW. Analysis of glucose responses to automated 
insulin suspension with sensor-augmented pump therapy. Diabetes Care 2012; 35(7): 1462-5. 
27. Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin suspension in 
response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011; 
34(9): 2023-5. 
28. Williams RM, Dunger DB. Insulin treatment in children and adolescents. Acta paediatrica 2004; 93(4): 
440-6. 
29. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents 
with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375(9716): 743-51. 
30. van Bon AC, Luijf YM, Koebrugge R, Koops R, Hoekstra JB, Devries JH. Feasibility of a portable 
bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. 
Diabetes Technol Ther 2013. DOI: 10.1089/dia.2013.0166. 
31. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-Logic artificial pancreas in home 
setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014; 15(2): 91-9. 
 
